Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Mar;28(1):49-53.
doi: 10.1007/s12022-016-9454-3.

TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma

Affiliations
Case Reports

TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma

Eun Ji Oh et al. Endocr Pathol. 2017 Mar.

Abstract

The cribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) is a rare thyroid neoplasm characterized by unique morphologic findings and association with familial adenomatous polyposis. The biologic behavior of this variant has been reported to behave similarly to classic PTC. We report a rare sporadic case of CMV-PTC occurring in a 45-year-old female with multiple lymph nodes and bone metastases, which were detected after total thyroidectomy and radioactive iodine remnant ablation. Molecular analyses of primary thyroid and metastatic tumor tissues revealed a telomerase reverse transcriptase (TERT) promoter mutation, but absence of BRAF, KRAS, NRAS, HRAS, and PIK3CA mutations. Over a 4-year follow-up period, structurally identifiable bone metastases were persistent, but serial post-operative serum thyroglobulin levels remained undetectable in the absence of thyroglobulin antibody. The literature was reviewed. This is the first case of aggressive CMV-PTC showing TERT promoter mutation. TERT promoter mutations may help in predicting aggressive clinical behavior in CMV-PTC. Postoperative serum thyroglobulin measurement may have no impact on clinical decision-making in this type of tumor.

Keywords: Biomarker; Cribriform-morular variant; Papillary thyroid carcinoma; Telomerase reverse transcriptase.

PubMed Disclaimer

Similar articles

Cited by

References

    1. World J Surg. 2006 May;30(5):775-9 - PubMed
    1. Int J Surg Pathol. 2012 Dec;20(6):629-32 - PubMed
    1. Histopathology. 1994 Dec;25(6):549-61 - PubMed
    1. J Biol Chem. 2007 Apr 13;282(15):11221-9 - PubMed
    1. J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16 - PubMed

Publication types

LinkOut - more resources